MannKind falls after licensing inhaled GLP-1 program with Rose Pharma

MannKind Corporation shares were trading lower on Wednesday as investors reacted to its licensing and collaboration deal for an inhaled, rapid-acting GLP-1 program. The company said it and Rose Pharma, Inc. entered an agreement to develop an inhaled, rapid-acting GLP-1 receptor agonist that combines Rose Pharma’s investigational molecule with MannKind’s Technosphere inhalation technology. Under the pact, MannKind will receive an equity interest and potential royalties, while Rose Pharma gets an exclusive worldwide license to use Technosphere technology to develop and commercialize ROSE-010 Technosphere.

MannKind said it will support formulation development and advance the program through pharmaceutical development services through completion of Phase 1b in weight management. 04). 15), leaving the stock in a choppy transition zone rather than a clean uptrend. The death cross that formed in March, with the 50-day falling below the 200-day, remains an overhang until price holds above the 200-day and pulls the longer averages higher.

34, indicating the stock is not stretched to an overbought or oversold extreme and can still move either way without needing a snapback. 50, a nearby round-number area where rebounds can stall, especially with the 200-day SMA close overhead. 50, where buyers previously stepped in; a break would put more focus back on the lower end of the 52-week range. 82, according to the signal cited in the source.

The stock is described as relatively strong on momentum factors even as it trades around key moving averages. The signal notes that MannKind’s Edge setup is momentum-leaning, with the scorecard mainly supported by Momentum and other pillars not provided. 50 zone to confirm the momentum read-through. The source also references Sept.

30.